A plain language summary of the results from the group of patients in the CHRYSALIS study with EGFR exon 20 insertion-mutated non-small-cell lung cancer who received amivantamab
Future Oncology · 2023
DOI: 10.2217/fon-2023-0284 ↗Kurz gefasst
Fachartikel in der Zeitschrift Future Oncology, 2023. Verfasst von Alexander Spira und 6 weiteren Autor:innen. Beteiligte Einrichtung: Virginia Cancer Specialists Research Institute, US Oncology Research, Fairfax, VA, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
WHAT IS THIS SUMMARY ABOUT?: This is a plain language summary of an article published in the Journal of Clinical Oncology in 2021. It describes the first results from 1 group of patients in the phase 1 CHRYSALIS study with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations. This part of the CHRYSALIS study (called cohort D) investigated the bispecific antibody amivantamab (brand name RYBREVANT®) in patients with non-small-cell lung cancer (NSCLC) with an EGFR ex20ins mutation. EGFR mutations are one of the most common causes of NSCLC tumors, with EGFR ex20ins mutations being more common among people of Asian descent. Patients who took part in this study had cancer that could not be removed by surgery, and whose cancer had worsened after receiving other forms of treatment, such as chemotherapy. Typically, patients with this type of mutation are difficult to treat or do not experience treatment response with commonly used therapies that target EGFR. WHAT WERE THE RESULTS?: The CHRYSALIS study took place between May 27, 2016, and June 8, 2020, in select hospitals in the USA, Japan and South Korea. In cohort D, amivantamab showed promising results, with an overall response rate of 40%. This means that 4 of every 10 patients in CHRYSALIS cohort D had tumors that shrank or were no longer measurable. Clinical Trial Registration: NCT02609776 (the CHRYSALIS Phase I Study) (ClinicalTrials.gov).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Virginia Cancer Specialists Research Institute, US Oncology Research, Fairfax, VA, USA.
- Institut Curie, Paris, France.
- Division of Cancer Sciences, Faculty of Biology, Medicine & Health, The University of Manchester & The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom.
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
- Columbia University Medical Center, New York, NY, USA.
- Abramson Cancer Center, University of Pennsylvania Health System, Philadelphia, PA, USA.
Zitieren
APA
Spira, A., Girard, N., Krebs, M., Park, K., Shu, C., Dougherty, L., & Cho, B. C. (2023). A plain language summary of the results from the group of patients in the CHRYSALIS study with EGFR exon 20 insertion-mutated non-small-cell lung cancer who received amivantamab. Future Oncology. https://doi.org/10.2217/fon-2023-0284
Vancouver
Spira A, Girard N, Krebs M, Park K, Shu C, Dougherty L, et al. A plain language summary of the results from the group of patients in the CHRYSALIS study with EGFR exon 20 insertion-mutated non-small-cell lung cancer who received amivantamab. Future Oncology. 2023. doi:10.2217/fon-2023-0284
BibTeX
@article{Spira2023,
author = {Spira, Alexander and Girard, Nicolas and Krebs, Matthew and Park, Keunchil and Shu, Catherine and Dougherty, Lindsay and Cho, Byoung Chul},
title = {A plain language summary of the results from the group of patients in the CHRYSALIS study with EGFR exon 20 insertion-mutated non-small-cell lung cancer who received amivantamab},
journal = {Future Oncology},
year = {2023},
doi = {10.2217/fon-2023-0284}
}
EUVIMED